Protocol Ledger

NCT06980480 · Phase III · RECRUITING

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Interventional Phase III clinical trial protocol NCT06980480 sponsored by Takeda in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-14 Enrollment: 183 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06980480
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)183 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06980480
Protocol FieldVerified Registry Value
NCT IdentifierNCT06980480
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment183 participants (ESTIMATED)
Registered Start Date2026-01-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI